Davis Polk Advised Pegbio On Its IPO And HKEX Listing

Davis Polk Advised Pegbio On Its IPO And HKEX Listing

Davis Polk advised PegBio Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange, as well as its international offering pursuant to Regulation S.

PegBio is a biotechnology company focused on the in-house discovery and development of innovative therapies—primarily peptide and small molecule drugs—for chronic diseases, with a particular emphasis on metabolic disorders.

The Davis Polk corporate team included Li He (Partner), Xuelin (Steve) Wang (Partner), and Jason Xu (Partner); Jennifer (Yujia) Jiang (Counsel – Registered Foreign Lawyer), Wendy Kan (Counsel); and Michelle Chow (Associate) and Jamie Lai (Associate). Members of the Davis Polk team are based in the firm’s Hong Kong and Beijing offices.

Click to know more about Davis Polk

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.